Skip to main content

Table 3 Frequency of anti-malarials used by hospitalized patients, Uganda, 2014

From: Quality of care for adult in-patients with malaria in a tertiary hospital in Uganda

Anti-malarial Number n, %
Patient-level
 Pre-admission, n = 97
  Artemether-Lumefantrine only 50 52
  Quinine only 22 23
  Sulfadoxine-Pyrimethamine only 9 9
  Artesunate only 5 5
  Coartem + Quinine only 4 4
  Duocotecxin only 2 2
  Artemether only 1 1
  Artesunate + Duocotexcin only 1 1
  P-alaxin + Quinine only 1 1
  Artemether + Quinine + Doxycycline only 1 1
  Dihydroartemisinin-Piperaquine only 1 1
 In-hospital, n = 100*
  Artesunate only± 47 47
  Quinine only~ 23 23
  Artemether-Lumefantrine only 15 15
  Artesunate + Artemether-Lumefantrine only   
  Quinine + Artemether/Lumefantrine only 3 3
  Sulfadoxine-Pyrimethamine only 2 2
  Artesunate + Quinine only 2 2
Drug-level
 Pre-admission, n = 105
  Artemether-Lumefantrine 54 51
  Quinine 28 27
  Sulfadoxine-Pyrimethamine 9 9
  Artesunate 6 6
  Duocotexcin 3 3
  Artemether 2 2
  Dihydroartemisinin-Piperaquine 2 2
  Doxycycline 1 1
 In-hospital, n = 113
  Artesunate 57 50
  Quinine 28 25
  Artemether-Lumefantrine 26 23
  Sulfadoxine-Pyrimethamine 2 2
  1. *Only 13% (11/83) of in-patients who received injectable artesunate or quinine received follow-up oral artemether-lumefantrine; ±68% (32/47) of the in-patients presented with both admission and discharge malaria diagnoses [median length of hospital stay: 4 (IQR, 3 to 5) days]; ~91% (21/23) of the in-patients had both admission and discharge malaria diagnoses [median length of hospital stay: 3 (IQR, 2 to 4) days]